• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Public Health (Oxf) . The extent of infectious SARS-CoV-2 shedding in an Argentinean cohort

tetano

Editor, Senior Moderator
J Public Health (Oxf)


. 2021 May 8;fdab145.
doi: 10.1093/pubmed/fdab145. Online ahead of print.
The extent of infectious SARS-CoV-2 shedding in an Argentinean cohort


Sebasti?n Blanco[SUP] 1 [/SUP], Juan Javier Aguilar[SUP] 1 [/SUP], Brenda Salom? Konigheim[SUP] 1 2 [/SUP], Luis Adrian Diaz[SUP] 1 2 [/SUP], Lorena Spinsanti[SUP] 1 [/SUP], Mauricio Beranek[SUP] 1 2 [/SUP], C?sar Collino[SUP] 3 [/SUP], Lab Central C?rdoba working group; Miguel Diaz[SUP] 3 [/SUP], Mar?a Gabriela Barb?s[SUP] 4 [/SUP], Sandra Ver?nica Gallego[SUP] 1 2 [/SUP]



Affiliations

Abstract

Background: To analyze the infectious extent of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) in different settings where prevention strategies are critical to limit infection spread, we evaluated SARS-COV-2 viability to guide public health policies regarding isolation criteria and infection control.
Methods: We attempted viral isolation in 82 nasopharyngeal swabs from 72 patients with confirmed SARS-COV-2 infection. Study population was divided into four groups: (i) Patients during the first week of symptoms; (ii) Patients with prolonged positive PCR; (iii) Healthcare workers from a hospital participating of an outbreak investigation, with SARS-COV-2 infection confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) and (iv) Recipients of convalescent immune plasma (CIP).Vero Cl76 cell-line (ATCC CRL-587) was used in assays for virus isolation. Plasma samples of CIP recipients were also tested with plaque-reduction neutralization test.
Results: We obtained infectious SARS-COV-2 isolates from 15/84 nasopharyngeal swabs. The virus could not be isolated from upper respiratory tract samples collected 10-day after onset of symptoms (AOS) in patients with mild-moderate disease.
Conclusion: The knowledge of the extent of SARS-CoV-2 infectivity AOS is relevant for effective prevention measures. This allows to discuss criteria for end isolation despite persistence of positive PCR and improve timing for hospital discharge with consequent availability of critical beds.

Keywords: COVID-19; SARS-CoV-2; infectivity; isolation; public health.
 
Back
Top Bottom